In April, Dr. Andrew Tie presented the following poster at the 2025 Congress of the European Society of Clinical Microbiology and Infectious Diseases. This work, originated by John Aitken’s team at Otakaro Pathways, shows mycobacteria in the ileal tissue of all tested Crohn’s disease subjects (18/18) and none in healthy controls (0/15).
Please enjoy the latest MAP research update by John Aitken of Otakaro Pathways.
March 24, 2020 is the 138th anniversary of Dr. Robert Koch’s famous meeting at the Berlin Physiological Society where he presented his findings on tuberculosis to a stunned audience. Researcher John Aitken (Otakaro Pathways, New Zealand) provides fresh insight into this historic event, and why it remains relevant in our fight against Crohn’s and MAP today.
by John Aitken and Kevin Taylor
The following abstract accompanied an oral presentation at a New Zealand veterinary conference in 2014, and it was a fair summary of our thinking at the time. Most of the problems outlined in the article have since been addressed by us. In addition, the contributing group has expanded considerably.
Christchurch Microbiologist May Have Cracked Crohn’s Disease
New today, two articles about John Aitken and his research into Crohn’s disease are making headlines in the New Zealand news.
This photo is that of a group of white cells in the blood of a Crohn’s patient. It is literally “One from the heart.”
In the plant world, endophytes exist within plants to perform essential functions in the plant – stimulation of plant immunity, competitive inhibition (making sure there is no room left for an invader) and production of chemicals capable of killing other bacteria (antibiotics). This is a process called “symbiosis.” Symbiosis occurs when two organisms co-exist and one, or both, organisms benefit from the relationship. In plants, endophytes have evolved to be part of the growth mechanisms of the plant. They are found in the roots and in the leaves.
What has this to do with Crohn’s disease?
It is now the end of 2015. For Crohn’s patients this year has been a time of great change. In the middle of the battle against this illness, there is some reason to hope.
In the midst of World War 2, Winston Churchill announced the change in fortunes for the British Empire, since the dark days of 1939, and instructed that the Church bells all over Britain be rung for the first time since the outbreak of the War. In his speech to the nation, he used the phrase: “Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
On October 19, 2015 John Aitken and his team presented details about their Mycobacterium avium subspecies paratuberculosis (MAP) research to attendees of the American College of Gastroenterology (ACG) meeting in Hawaii. The poster that Mr. Aitken and his team presented is shared here. It discusses how his team has isolated Son of MAP in the blood of Crohn’s disease patients, a novel idea to many in the GI field.
[button link=”http://thecrohnsinfection.org/john-aitkens-map-research-acg/” type=”big”] View the Research[/button]
We are at the dawning of a new era in the use of antibiotics.
For some 20 years there have been attempts to use antibiotics in the treatment of Crohn’s disease. Although most trials have delivered mixed results, this direction has been reinforced by the association of Mycobacterium avium ssp paratuberculosis (MAP) with Crohn’s disease.
The main principle of judicious and effective antibiotic usage has been the targeting of the suspected pathogen with a therapy that is both specific and directed. This has been a difficult job, as there has been, up to now, no protocol that will ensure the reliable isolation of the pathogen from the patient. The model that is used for new compounds against MAP-associated organisms is directly related to the proven therapies for tuberculosis, and this has been a wise model to follow.
[button link=”http://thecrohnsinfection.org/john-aitken-antibiotics/” type=”big”] Read the Full Article[/button]
